CaMKII (Calcium/Calmodulin-Dependent Protein Kinase II) is a serine/threonine protein kinase that is abundant in the brain and plays critical roles in synaptic plasticity, learning, and memory. CaMKII is activated by calcium/calmodulin and can remain active even after calcium levels return to baseline, making it a molecular switch for synaptic memory traces. The holoenzyme consists of 12 subunits arranged in two stacked hexameric rings.
CaMKII forms a large holoenzyme (~300 nmol/L in the postsynaptic density) composed of 12 subunits (typically 2 α, 10 β in forebrain). Each subunit contains an N-terminal catalytic domain, a regulatory segment with autoinhibitory domain, and a C-terminal association domain. The regulatory segment contains a T286 autophosphorylation site (α subunit) that confers autonomy. CaMKII can be activated by Ca²⁺/calmodulin and then autophosphorylate to become calcium-independent.
CaMKII is the major calcium-activated kinase at the postsynaptic density. Key functions include: (1) phosphorylation of AMPA receptor subunits to enhance channel conductance; (2) phosphorylation of NMDA receptor NR2B subunits to regulate channel properties; (3) phosphorylation of SynGAP to modulate synaptic plasticity; (4) regulation of gene transcription through CREB. CaMKII activity is essential for LTP, LTD, and memory formation. T286 autophosphorylation creates a molecular memory trace.
CaMKII dysfunction is implicated in multiple neurological disorders. In Alzheimer's disease, amyloid-beta oligomers dysregulate CaMKII signaling, contributing to synaptic dysfunction and memory deficits. Reduced CaMKII autophosphorylation is observed in AD brains. CaMKII alterations are also involved in epilepsy, autism, and schizophrenia. Targeting CaMKII may offer therapeutic benefits for cognitive impairment.
CaMKII modulators have been explored for cardiac disease and cancer. In neurodegeneration, strategies to restore CaMKII function include: (1) small molecule activators that enhance autophosphorylation; (2) peptides that stabilize CaMKII holoenzyme; (3) gene therapy to increase CaMKIIα expression. However, CaMKII has complex roles and global activation may have adverse effects.